Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

• ClinicalTrials.gov Identifier: NCT05493709
• Recruitment Status: Not yet recruiting
• First Posted: August 9, 2022
• Last Update Posted: August 9, 2022
• Sponsor: Foresee Pharmaceuticals Co., Ltd.
• Collaborators: QPS Holdings LLC; GeneScience Pharmaceuticals Co., Ltd.
• Information provided by (Responsible Party): Foresee Pharmaceuticals Co., Ltd.

Study Description

Brief Summary:

The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with central (gonadotropin-dependent) precocious puberty, when administered as two injections six months apart.

Condition or disease	Intervention/treatment	Phase
Puberty; Precocious, Central	Drug: Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide	Phase 3

Detailed Description:

This is a multi-center, open-label, single-arm study. All subjects will be pediatric patients with central precocious puberty judged to be candidates for GnRH (gonadotropin releasing hormone) analog therapy, and all will receive two injections of FP-001 42 mg six-month apart in an unblinded fashion.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 93 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open-label, Single Arm, Multicenter, Phase III Study on the Efficacy, Safety, and Pharmacokinetics of FP-001 42 mg Controlled Release in Patients With Central (Gonadotropin-Dependent) Precocious Puberty
• Estimated Study Start Date: October 15, 2022
• Estimated Primary Completion Date: October 30, 2025
• Estimated Study Completion Date: December 31, 2025

Arms and Interventions

Arm	Intervention/treatment
Experimental: FP-001 42 mg; All subjects will be pediatric patients with central precocious puberty. They will be injected twice with a depot formulation containing 42 mg of Leuprolide. The first dose on day 0 the second dose on week 24 (six months apart).	Drug: Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide; All subjects will be pediatric patients with central precocious puberty. They will be injected twice with a depot formulation containing 42 mg of Leuprolide. The first dose on day 0 the second dose on week 24 (six months apart).

Outcome Measures

Primary Outcome Measures :

1. Efficacy of Leuprolide Mesylate (FP-001 42 mg) [ Time Frame: 48 weeks ]
   The percentage of patients with serum LH concentrations < 4 mIU/mL 60 minutes following an abbreviated GnRHa stimulation test at Visit 6 (Week 24).

Secondary Outcome Measures :

1. Effect of FP-001 42 mg on bone age progression [ Time Frame: 24 and 48 weeks ]
   Evaluate the changes in bone age progression from the baseline to Weeks 24 and 48 using centralized analysis of wrist x-ray
2. Effect of FP-001 42 mg on growth rate [ Time Frame: 48 weeks ]
   Evaluate the changes in growth rate and bone age advancement relative to chronological age from baseline to end of study using height in meters
3. Effect of FP-001 42 mg on physical signs of puberty [ Time Frame: 48 weeks ]
   Evaluate the change in physical signs of puberty as measure by Tanner stages from baseline to end of study
4. Effect of FP-001 42 mg on suppression of physical signs of puberty [ Time Frame: 48 weeks ]
   Evaluate the percentage of patients with suppression of physical signs of puberty
5. Acute-On-Chronic (AOC) phenomenon of serum testosterone and LH [ Time Frame: 48 weeks ]
   Evaluate The proportion of subjects exhibiting "acute-on-chronic" phenomenon (i.e., related to the second dose of FP-001 42 mg)

Eligibility Criteria

• Ages Eligible for Study: 2 Years to 9 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Females aged 2 to 8 years (inclusive) or males aged 2 to 9 years (inclusive).
2. Confirmed diagnosis of CPP within 12 months of Baseline Visit (Day 0) but have not received prior GnRHa treatment for CPP.
3. Pubertal-type LH response at 60 minutes post GnRHa stimulation test before treatment initiation > 5 mIU/mL.
4. Clinical evidence of puberty, defined as Tanner stage ≥ 2 for breast development in females or testicular volume ≥ 4 mL in males.
5. Willing and able to participate in the study.
6. Difference between bone age (Greulich and Pyle method) and chronological age ≥ 1 year.
7. Bone age < 13 years for girls and < 14 years for boys.
8. Signed Institutional Review Board/Independent Ethics Committee (IRB/IEC)-approved informed consent form (ICF) by one or both parents (per IRB/IEC requirements), by the custodial parent(s) or by the legal guardian(s) (if required).
9. Signed Assent by patients as per IRB/IEC requirements.

Exclusion Criteria:

1. Gonadotropin-independent (peripheral) precocious puberty: extra pituitary secretion of gonadotropins or gonadotropin-independent gonadal or adrenal sex steroid secretion. This includes true CPP triggered by other conditions, such as congenital adrenal hyperplasia.
2. Prior or current GnRH treatment for CPP.
3. Non-progressing isolated premature thelarche.
4. Presence of an unstable intracranial tumor or an intracranial tumor requiring neurosurgery or cerebral irradiation. Patients with hamartomas or adenomas not requiring surgery are eligible.
5. Any other condition, chronic illness or treatment that, in the opinion of the Investigator, may interfere with growth or other study endpoints (e.g., chronic steroid use [except mild topical steroids], renal failure, diabetes, moderate to severe scoliosis, previously treated intracranial tumor).
6. Prior or current therapy with medroxyprogesterone acetate, growth hormone or insulin-like growth factor-1 (IGF-1).
7. Major medical or psychiatric illness that could interfere with study visits.
8. Diagnosis of short stature (i.e., 2.25 standard deviations (SD) below the mean height for age).
9. Positive urine pregnancy test.
10. Known hypersensitivity to GnRH or related compounds.
11. Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the patients to participate in the study.
12. Any other condition(s) which could significantly interfere with Protocol compliance.
13. Treatment with an investigational product within 5 half-lives of that product in prior clinical studies before the baseline visit (Day 0).
14. Known history of seizures, epilepsy, and/or central nervous system disorders that may be associated with seizures or convulsions.
15. Prior (within 6 months of Baseline (Day 0)) or current use of medications that, per Investigator opinion, have been associated with seizures or convulsions.

Contacts and Locations

Contacts

Contact: Susan Shelby, PhD; 13026902258; susan.shelby@foreseepharma.com

Contact: Bill Miller Miller, PhD; bill.miller@foreseepharma.com

Sponsors and Collaborators

Foresee Pharmaceuticals Co., Ltd.

QPS Holdings LLC

GeneScience Pharmaceuticals Co., Ltd.

Investigators

• Study Director: Susan Shelby, PhD; Foresee Pharmacuticals co., Ltd

More Information

• Responsible Party: Foresee Pharmaceuticals Co., Ltd.
• ClinicalTrials.gov Identifier: NCT05493709
• Other Study ID Numbers: FP-001-CP-001
• First Posted: August 9, 2022
• Last Update Posted: August 9, 2022
• Last Verified: August 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Puberty, Precocious; Gonadal Disorders; Endocrine System Diseases; Leuprolide; Fertility Agents, Female; Fertility Agents; Reproductive Control Agents; Physiological Effects of Drugs; Antineoplastic Agents, Hormonal; Antineoplastic Agents